Guggenheim Capital’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-21,572
| Closed | -$45.7K | – | 1893 |
|
|
2023
Q3 | $45.7K | Sell |
21,572
-35,287
| -62% | -$74.8K | ﹤0.01% | 1827 |
|
|
2023
Q2 | $271K | Sell |
56,859
-738
| -1% | -$3.51K | ﹤0.01% | 1687 |
|
|
2023
Q1 | $328K | Sell |
57,597
-63,320
| -52% | -$361K | ﹤0.01% | 1651 |
|
|
2022
Q4 | $1.22M | Sell |
120,917
-6,301
| -5% | -$63.6K | 0.01% | 1057 |
|
|
2022
Q3 | $2.85M | Sell |
127,218
-12,756
| -9% | -$286K | 0.03% | 707 |
|
|
2022
Q2 | $3.47M | Buy |
139,974
+7,599
| +6% | +$188K | 0.03% | 687 |
|
|
2022
Q1 | $5.13M | Sell |
132,375
-24,513
| -16% | -$950K | 0.03% | 639 |
|
|
2021
Q4 | $9.18M | Buy |
156,888
+17,225
| +12% | +$1.01M | 0.05% | 457 |
|
|
2021
Q3 | $8.28M | Buy |
139,663
+35,489
| +34% | +$2.1M | 0.05% | 452 |
|
|
2021
Q2 | $9.04M | Sell |
104,174
-1,756
| -2% | -$152K | 0.05% | 428 |
|
|
2021
Q1 | $8.73M | Buy |
105,930
+13,522
| +15% | +$1.11M | 0.06% | 410 |
|
|
2020
Q4 | $8.4M | Buy |
92,408
+34,100
| +58% | +$3.1M | 0.05% | 392 |
|
|
2020
Q3 | $2.33M | Sell |
58,308
-250
| -0.4% | -$9.99K | 0.02% | 823 |
|
|
2020
Q2 | $2.01M | Buy |
58,558
+24,690
| +73% | +$847K | 0.02% | 880 |
|
|
2020
Q1 | $752K | Buy |
33,868
+13,903
| +70% | +$309K | 0.01% | 1209 |
|
|
2019
Q4 | $391K | Buy |
19,965
+7,312
| +58% | +$143K | ﹤0.01% | 1697 |
|
|
2019
Q3 | $197K | Buy |
+12,653
| New | +$197K | ﹤0.01% | 2007 |
|
|
2017
Q4 | – | Sell |
-10,636
| Closed | -$43K | – | 2742 |
|
|
2017
Q3 | $43K | Buy |
10,636
+336
| +3% | +$1.36K | ﹤0.01% | 2705 |
|
|
2017
Q2 | $33K | Buy |
+10,300
| New | +$33K | ﹤0.01% | 2754 |
|